Document ID: FDA-2023-N-3499-0001
Agency: fda
Document Type: Notice
Title: Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Alternative Form of Hearing
Posted Date: 2023-08-24T04:00Z

[Federal Register Volume 88, Number 163 (Thursday, August 24, 2023)]
[Notices]
[Pages 57958-57959]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-18241]

[[Page 57958]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2023-N-3499]

Endocrinologic and Metabolic Drugs Advisory Committee; Notice of 
Alternative Form of Hearing

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of alternative form of hearing.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) announces an 
alternative form of hearing regarding the Center for Drug Evaluation 
and Research's (CDER's) proposal to refuse to approve ITCA 650 
(exenatide in DUROS device), a drug-device combination product that is 
the subject of a new drug application (NDA) submitted by Intarcia 
Therapeutics, Inc. (Intarcia). CDER is holding a public hearing before 
an advisory committee under FDA regulations as an alternative form of 
hearing.

DATES: The meeting will be held virtually on September 21, 2023, from 9 
a.m. to 5:30 p.m. Eastern Time.

ADDRESSES: All meeting participants will be heard, viewed, captioned, 
and recorded for this advisory committee meeting via an online 
teleconferencing and/or video conferencing platform. Answers to 
commonly asked questions including information regarding special 
accommodations due to a disability may be accessed at: https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.

FOR FURTHER INFORMATION CONTACT: LaToya Bonner, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-
796-2855, email: [email protected]; or FDA Advisory Committee 
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC 
area).

SUPPLEMENTARY INFORMATION: 
    Background: This advisory committee meeting is being held pursuant 
to a March 24, 2023, letter from the Chief Scientist of FDA, Dr. 
Namandj[eacute] N. Bumpus, wherein she granted Intarcia's request under 
Sec.  12.32(b)(3)(ii) (21 CFR 12.32(b)(3)(ii)) for a public hearing 
before an advisory committee in lieu of a formal evidentiary public 
hearing under part 12 (21 CFR part 12).
    Intarcia submitted NDA 209053 for ITCA 650 (exenatide in DUROS 
device), a novel drug-device combination product on November 21, 2016, 
under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act 
(FD&C Act) (21 U.S.C. 355(b)(1)). On September 21, 2017, CDER issued a 
complete response (CR) letter to Intarcia under Sec.  314.110(a) (21 
CFR 314.110(a)) stating that NDA 209053 could not be approved in its 
present form, describing the specific deficiencies and, where possible, 
recommending ways that Intarcia might remedy these deficiencies. On 
September 9, 2019, Intarcia resubmitted the NDA under section 505(b)(1) 
of the FD&C Act. On March 9, 2020, CDER issued a second CR letter 
stating that NDA 209053 could not be approved in its present form, 
describing the specific deficiencies and, where possible, recommending 
ways that Intarcia might remedy these deficiencies. The CR letters 
stated that Intarcia is required either to resubmit the application, 
fully addressing all deficiencies listed in the letter, or take other 
actions available under Sec.  314.110 (i.e., resubmit the application, 
withdraw the application, or request an opportunity for a hearing). 
Applicable regulations, including 21 CFR 10.75, also provide a 
mechanism for applicants to obtain formal review of one or more 
decisions reflected in a CR letter.
    On March 16, 2021, Intarcia submitted a request under Sec.  
314.110(b)(3) for an opportunity for a hearing on whether there are 
grounds under section 505(d) of the FD&C Act for denying approval of 
NDA 209053. In the Federal Register of September 2, 2021, FDA published 
a notice of opportunity for a hearing (NOOH) regarding CDER's proposal 
to refuse to approve NDA 209053 submitted by Intarcia for ITCA 650 (86 
FR 49334). The NOOH gave Intarcia an opportunity to request a hearing 
before the Commissioner of Food and Drugs on CDER's proposal to refuse 
to approve NDA 209053. On September 13, 2021, Intarcia submitted a 
notice of participation and request for a hearing. Intarcia submitted 
data, information, and analyses in support of its hearing request on 
November 1, 2021, and February 15, 2022.
    On July 29, 2022, CDER issued, via email to Intarcia, a proposed 
order proposing to refuse to approve NDA 209053 in its present form 
(see Docket No. FDA-2021-N-0874). Intarcia responded to CDER's proposed 
order on October 10, 2022.
    On February 7, 2023, the Chief Scientist of FDA issued a letter to 
Intarcia and CDER that stated, in part: ``Under 21 CFR 12.32(a), a 
person seeking a hearing under 21 CFR part 12 may request an 
alternative form of hearing, such as a hearing before a public advisory 
committee under 21 CFR part 14.'' Dr. Bumpus stated that she would 
grant a request from Intarcia for an alternative form of hearing under 
part 14 (21 CFR part 14) in lieu of a formal evidentiary hearing under 
part 12. On February 20, 2023, Intarcia submitted a request in the form 
of a citizen petition under 21 CFR 10.30, requesting a public hearing 
before an advisory committee under part 14 in lieu of Intarcia's 
pending request for a formal evidentiary hearing under part 12. On 
March 24, 2023, Dr. Bumpus issued a letter granting Intarcia's request 
for an alternative form of hearing.
    Accordingly, CDER is holding this meeting pursuant to the March 24, 
2023, letter from Dr. Bumpus, wherein she granted Intarcia's request 
under Sec.  12.32(b)(3)(ii) for a public hearing before an advisory 
committee in lieu of a formal evidentiary hearing. This document serves 
as the notice of an alternative form of hearing as required under Sec.  
12.32(e).
    Subject of Alternative Form of Hearing: CDER's proposed order to 
refuse to approve ITCA 650 (exenatide in DUROS device) is the subject 
of the alternative form of hearing before the Endocrinologic and 
Metabolic Drugs Advisory Committee (see Docket No. FDA-2021-N-0874).
    Parties to the Alternative Form of Hearing: Intarcia Therapeutics, 
Inc. and the Center for Drug Evaluation and Research are the parties to 
the alternative form of hearing before the Endocrinologic and Metabolic 
Drugs Advisory Committee.
    Issues To Be Discussed: The issues presented at the hearing will be 
those related to the safety and efficacy of ITCA 650, a drug-device 
combination product that is the subject of an NDA submitted by Intarcia 
(NDA 209053), for the proposed indication, as an adjunct to diet and 
exercise, to improve glycemic control in adults with type 2 diabetes 
mellitus.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. 1001 et seq.). This meeting notice also serves 
as notice that, pursuant to 21 CFR 10.19, the requirements in 21 CFR 
14.22(b), (f), and (g) relating to the location of advisory committee 
meetings are hereby waived to allow for this meeting to take place 
using an online meeting platform. This waiver is in the interest of 
allowing greater transparency and opportunities for public 
participation, in addition to convenience for advisory committee 
members, speakers, and guest speakers. No participant will be 
prejudiced by

[[Page 57959]]

this waiver, and that the ends of justice will be served by allowing 
for this modification to FDA's advisory committee meeting procedures.

    Dated: August 21, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-18241 Filed 8-23-23; 8:45 am]
BILLING CODE 4164-01-P